Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Testicular Neoplasms 5Prostatic Neoplasms 5Urinary Bladder Neoplasms 4Testicular Germ Cell Tumor 4Seminoma 3Ovarian Neoplasms 3Endodermal Sinus Tumor 3Central Nervous System Neoplasms 3Urethral Neoplasms 2Teratoma 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Embryonal 2Wilms Tumor 1Ureteral Neoplasms 1Stomach Neoplasms 1Renal Pelvis and Ureter Urothelial Carcinoma 1Pancreatic Neoplasms 1Pain 1Neoplasms, Germ Cell and Embryonal 1Neoplasm Metastasis 1Melanoma 1Kidney Neoplasms 1Infiltrating Bladder Urothelial Carcinoma 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Dysgerminoma 1Carcinoma, Transitional Cell 1Breast Neoplasms 1

Interventions

pembrolizumab 75Nivolumab 46Cyclophosphamide 25aldesleukin 23fludarabine 16atezolizumab 15Ipilimumab 15Interleukin-2 14Radiosurgery 13Paclitaxel 13Specimen Handling 12Magnetic Resonance Spectroscopy 11Carboplatin 11fludarabine phosphate 9Docetaxel 9durvalumab 8Cisplatin 8cemiplimab 7Bevacizumab 7Radiotherapy 6Gemcitabine 6Biopsy 6spartalizumab 5avelumab 5Pemetrexed 5Oxaliplatin 5Immune Checkpoint Inhibitors 5Filgrastim 5Cryosurgery 5Blood Specimen Collection 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × pegfilgrastim × Genitourinary × Clear all
NCT02650635 2018-09-05

TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic, Persistent, Recurrent, or Progressive Solid Tumors

Mayo Clinic

Phase 1 Terminated
4 enrolled
BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡